FDG-PET & Brain Insulin Resistance

Condition: Parkinson's disease, insulin resistance


Key Inclusion Criteria

  • Diagnosis of idiopathic Parkinson's disease
  • Concurrent enrollment in the study, Liraglutide in Parkinson's Disease
  • Ability to safely undergo FDG-PET imaging

Key Exclusion Criteria

  • Discontinued or halted participation in Liraglutide in Parkinson's Disease
  • Allergy to tracer used for PET imaging or prior allergic reaction to iodine or contrast
  • Pregnant or breastfeeding

Full Study Name

FDG-PET as a Biomarker for Brain Insulin Resistance in Parkinson's Disease and the Impact of Liraglutide (IRB no. 47518)


This study aims to determine the effects of a drug called liraglutide on brain glucose metabolism in Parkinson’s disease (PD) patients. The study focuses on patients diagnosed with idiopathic PD who have already agreed to participate in another study, Liraglutide in Parkinson's Disease. Researchers will utilize imaging techniques to monitor changes in glucose metabolism (the way the brain uses energy) as a result of liraglutide use in PD. A brain imaging procedure, fluorodeoxyglucose-positron emission tomography (FDG-PET) scan, will also enable researchers to better understand glucose metabolism in patients with insulin resistance and Parkinson’s disease. The use of liraglutide in this study is investigational.

Principal Investigator

Michele Tagliati, MD